Form 4: Telesis Bio Inc. Director Jami Nachtsheim Reports Stock and Option Grants

Director Jami Nachtsheim reports the acquisition of restricted stock units and stock options in Telesis Bio Inc.

Summary

• On July 6, 2023, Jami Nachtsheim, a director of Telesis Bio Inc., was granted 46,752 restricted stock units (RSUs) and stock options for 70,129 shares at an exercise price of $1.54.
• On May 1, 2024, Nachtsheim was granted an additional 34,297 RSUs and stock options for 30,362 shares at an exercise price of $0.3557.
• The RSUs represent a contingent right to receive one share of Telesis Bio Inc.'s common stock for each RSU.
• Vesting of the RSUs and stock options is contingent upon Nachtsheim's continued service to the company, with 100% vesting on the earlier of the one-year anniversary of the grant date or the date of the annual meeting of the Issuer's stockholders following the date of grant.
• As of May 1, 2024, Nachtsheim beneficially owns 101,679 shares of common stock directly and holds options for 30,362 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock and option grants, which are common compensation practices. The grants themselves can be seen as a positive sign of aligning management interests with shareholders, but the filing itself is simply a factual disclosure.

Positives

• The granting of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the granted RSUs and stock options.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent.
• Vesting schedules tied to continued service are standard practice to align executive interests with long-term shareholder value.
• The specific amounts and terms of the grants would need to be compared to peer companies to assess their competitiveness.

Stakeholder Impact

• Shareholders: The grants dilute ownership slightly but align management's interests with stock performance.
• Employees: The grants can boost morale and incentivize performance.

Key Dates

Keywords

Telesis Bio Inc., TBIO, Form 4, Jami Nachtsheim, Director, RSU, Stock Options, Beneficial Ownership, Vesting